LionTCR is a leading brand that specializes in developing innovative immunotherapies to combat viral infections and viral-related cancers, with a particular focus on the Asian population. With over a decade of extensive research and development, LionTCR has created a groundbreaking product that harnesses the patient's own immune system to eradicate HBV-related hepatocellular carcinoma (HCC), a type of liver cancer. Their flagship product, personalized TCR-T cell therapy, has demonstrated remarkable clinical safety and efficacy in the treatment of HBV-related HCC, recurrent HCC post liver transplant, and chronic HBV infection.

With the largest patented TCR library in the world, LionTCR covers 80% of the patient population with a diverse range of HLA types, predominantly prevalent in Asia. LionTCR's state-of-the-art GMP production facility ensures the manufacturing of their proprietary therapy adheres to strict quality guidelines. Their mRNA technology enables the transient expression of TCRs on T-cells, providing enhanced safety features and potential future use in other cancer treatments.

With proven clinical success, LionTCR's personalized treatment has demonstrated an approximately 3-fold increase in survival time compared to standard care medications in Phase 1 studies. By leveraging the power of the patient's immune system, LionTCR is revolutionizing cancer treatment and providing hope for patients in need